vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and RAYONIER INC (RYN). Click either name above to swap in a different company.

Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $117.5M, roughly 1.4× RAYONIER INC). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -81.9%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 1.7%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Rayonier Inc., headquartered in Wildlight, Florida is a timberland real estate investment trust ("REIT") with assets located in softwood timber growing regions in the United States and New Zealand. Its core business segments are timber and real estate.

ESPR vs RYN — Head-to-Head

Bigger by revenue
ESPR
ESPR
1.4× larger
ESPR
$168.4M
$117.5M
RYN
Growing faster (revenue YoY)
ESPR
ESPR
+225.7% gap
ESPR
143.7%
-81.9%
RYN
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
1.7%
RYN

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
RYN
RYN
Revenue
$168.4M
$117.5M
Net Profit
$25.9M
Gross Margin
41.9%
Operating Margin
50.6%
23.0%
Net Margin
22.1%
Revenue YoY
143.7%
-81.9%
Net Profit YoY
-92.1%
EPS (diluted)
$0.32
$0.14

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
RYN
RYN
Q4 25
$168.4M
$117.5M
Q3 25
$87.3M
$177.5M
Q2 25
$82.4M
$106.5M
Q1 25
$65.0M
$82.9M
Q4 24
$69.1M
$650.5M
Q3 24
$51.6M
$124.1M
Q2 24
$73.8M
$99.6M
Q1 24
$137.7M
$113.7M
Net Profit
ESPR
ESPR
RYN
RYN
Q4 25
$25.9M
Q3 25
$-31.3M
$43.2M
Q2 25
$-12.7M
$408.7M
Q1 25
$-40.5M
$-3.4M
Q4 24
$327.1M
Q3 24
$-29.5M
$28.8M
Q2 24
$-61.9M
$1.9M
Q1 24
$61.0M
$1.4M
Gross Margin
ESPR
ESPR
RYN
RYN
Q4 25
41.9%
Q3 25
32.9%
Q2 25
29.7%
Q1 25
21.7%
Q4 24
53.8%
Q3 24
30.4%
Q2 24
25.4%
Q1 24
24.3%
Operating Margin
ESPR
ESPR
RYN
RYN
Q4 25
50.6%
23.0%
Q3 25
-11.4%
23.5%
Q2 25
8.6%
13.7%
Q1 25
-34.0%
0.1%
Q4 24
-6.4%
47.7%
Q3 24
-31.0%
15.2%
Q2 24
3.5%
4.6%
Q1 24
52.5%
7.6%
Net Margin
ESPR
ESPR
RYN
RYN
Q4 25
22.1%
Q3 25
-35.9%
24.3%
Q2 25
-15.4%
383.6%
Q1 25
-62.2%
-4.1%
Q4 24
45.1%
Q3 24
-57.2%
23.2%
Q2 24
-83.9%
1.9%
Q1 24
44.3%
1.2%
EPS (diluted)
ESPR
ESPR
RYN
RYN
Q4 25
$0.32
$0.14
Q3 25
$-0.16
$0.28
Q2 25
$-0.06
$2.63
Q1 25
$-0.21
$-0.02
Q4 24
$-0.14
$2.18
Q3 24
$-0.15
$0.19
Q2 24
$-0.33
$0.01
Q1 24
$0.34
$0.01

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
RYN
RYN
Cash + ST InvestmentsLiquidity on hand
$167.9M
$842.9M
Total DebtLower is stronger
$845.3M
Stockholders' EquityBook value
$-302.0M
$2.2B
Total Assets
$465.9M
$3.4B
Debt / EquityLower = less leverage
0.38×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
RYN
RYN
Q4 25
$167.9M
$842.9M
Q3 25
$92.4M
$919.6M
Q2 25
$86.1M
$892.3M
Q1 25
$114.6M
$216.2M
Q4 24
$144.8M
$303.1M
Q3 24
$144.7M
$51.9M
Q2 24
$189.3M
$120.2M
Q1 24
$226.6M
$142.1M
Total Debt
ESPR
ESPR
RYN
RYN
Q4 25
$845.3M
Q3 25
$845.1M
Q2 25
$844.9M
Q1 25
$1.0B
Q4 24
$1.0B
Q3 24
$1.3B
Q2 24
$1.4B
Q1 24
$1.4B
Stockholders' Equity
ESPR
ESPR
RYN
RYN
Q4 25
$-302.0M
$2.2B
Q3 25
$-451.4M
$2.3B
Q2 25
$-433.5M
$2.3B
Q1 25
$-426.2M
$1.9B
Q4 24
$-388.7M
$1.8B
Q3 24
$-370.2M
$1.8B
Q2 24
$-344.2M
$1.8B
Q1 24
$-294.3M
$1.8B
Total Assets
ESPR
ESPR
RYN
RYN
Q4 25
$465.9M
$3.4B
Q3 25
$364.0M
$3.5B
Q2 25
$347.1M
$3.5B
Q1 25
$324.0M
$3.4B
Q4 24
$343.8M
$3.5B
Q3 24
$314.1M
$3.5B
Q2 24
$352.3M
$3.5B
Q1 24
$373.1M
$3.6B
Debt / Equity
ESPR
ESPR
RYN
RYN
Q4 25
0.38×
Q3 25
0.37×
Q2 25
0.37×
Q1 25
0.55×
Q4 24
0.59×
Q3 24
0.72×
Q2 24
0.75×
Q1 24
0.74×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
RYN
RYN
Operating Cash FlowLast quarter
$45.2M
$256.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
0.0%
Cash ConversionOCF / Net Profit
9.91×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
RYN
RYN
Q4 25
$45.2M
$256.7M
Q3 25
$-4.3M
$116.2M
Q2 25
$-31.4M
$61.0M
Q1 25
$-22.6M
$27.7M
Q4 24
$-35.0M
$261.6M
Q3 24
$-35.3M
$66.2M
Q2 24
$-7.2M
$55.3M
Q1 24
$53.8M
$52.3M
Free Cash Flow
ESPR
ESPR
RYN
RYN
Q4 25
Q3 25
$99.9M
Q2 25
Q1 25
Q4 24
Q3 24
$-35.5M
$42.2M
Q2 24
$-7.3M
Q1 24
$53.8M
FCF Margin
ESPR
ESPR
RYN
RYN
Q4 25
Q3 25
56.3%
Q2 25
Q1 25
Q4 24
Q3 24
-68.7%
34.0%
Q2 24
-9.9%
Q1 24
39.0%
Capex Intensity
ESPR
ESPR
RYN
RYN
Q4 25
0.0%
Q3 25
0.0%
9.2%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.0%
Q3 24
0.3%
19.3%
Q2 24
0.1%
Q1 24
0.1%
Cash Conversion
ESPR
ESPR
RYN
RYN
Q4 25
9.91×
Q3 25
2.69×
Q2 25
0.15×
Q1 25
Q4 24
0.80×
Q3 24
2.30×
Q2 24
29.07×
Q1 24
0.88×
38.54×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

RYN
RYN

Real Estate Segment$42.3M36%
Pacific Northwest Timber Segment$19.8M17%
Stumpage Pay As Cut$19.3M16%
Improved Development$14.8M13%
Nontimber$13.2M11%
License Revenue Primarily From Hunting$5.3M4%
Land Based Solutions$2.9M2%

Related Comparisons